#Efficacy

Andrew Little

anthlittle

Two sort of contradictory thoughts on the one vs two dose argument, with the obvious caveat that I know very little about vaccines, but still based on some of my

James Krellenstein

jbkrell

I am a little confused by this @nytimes reporting by @MarcSantoraNYT and @RebeccaDRobbins on the new AZD1222 data. First of all, the claim that this data is the “first” to

Dinesh S. Thakur

d_s_thakur

This is a limited point about availability of efficacy data for vaccines under development in the context of the approval for CovidShield and Covaxin in India. There have been many

Dr Zoë Hyde

DrZoeHyde

Thread summarising an important presentation on the AstraZeneca trial results for South Africa.Key points: Efficacy initially seemed to be ~75%, but dropped to 22% against SA variant. Past COVID-19

Theo Sanderson

theosanderson

1/ The MHRA has approved a longer gap between doses for both the AstraZeneca vaccine and the Pfizer vaccine. The latter has concerned some people. Specifically many are citing a

Tim Cook

doctimcook

I've tried to add to @COVID19actuary @ActuaryByDay excellent graph from http://www.covid-arg.com & look at how vaccination impacts hospital & ICU admissionSeveral assumptions- assumed vaccination 100% protective (its best

Eric Feigl-Ding

DrEricDing

BREAKING—new #COVID19 vaccine efficacy study from Israel concludes that Pfizer/BioNTech's jab is up to 85% effective after the first dose after 15 days to day 28—and even 75% including asymptomatic

BK Titanji #ILookLikeAScientist

Boghuma

Preprint-ChAdOx1 trial in HIV(-) people in South Africa. 23/717 (3.2%) placebo & 19/750 (2.5%) vaccine recipients developed mild-moderate # COVID19. Of the cases, 39/42 (92.9%) were the B.1.351 variant –

Andrew💙Croxford

andrew_croxford

COMMENT: I was startled by the decision to delay the second dose of the Pfizer vaccine, mentioned at today’s morning presser which focused mainly on the Astra/Ox vaccine. In the

F. Perry Wilson, MD MSCE

fperrywilson

Looking through the @pfizer data submitted to #vrbpac now. Fascinating stuff here. Thread. 1/ Baseline characteristics. Not bad. ~10% Black. Would have liked to see more >=75 years old. 2/

Dr. Angela Rasmussen

angie_rasmussen

Good and bad news about the Novavax protein subunit vaccine. 90% efficacy in the UK, but only ~50% in South Africa, largely because of the B.1.351 variant. Hopeful news too:

Joshua Gans

joshgans

Time for a threat on the J&J vaccine whose efficacy results were released today. https://www.nytimes.com/2021/01/29/health/covid-vaccine-johnson-and-johnson-variants.html?action=click&module=Spotlight&pgtype=Homepage [1/n] First

Natalie E. Dean, PhD

nataliexdean

What is the best endpoint for Phase 3 vaccine trials? Disease of any severity? Severe disease? Infection? Most trials have selected the first, but this @PostOpinions piece is critical of

Maneesh

Maneesh312

We have two vaccines in India Covishield by SII and Covaxin by BB. One is a botched up trial and another with no phase-3 trial data and phase 1 and

𝔻𝕣𝕃𝕪𝕟𝕟𝔽𝕪𝕟𝕟 🇺🇸 👩🏽‍⚕️🧬💊🥼🩺🦠🌿

LynnFynn3

1) Doing a little light reading... The @Pfizer Study (as well as the other Covid-19 Trials) is a disgrace. Inject 44,000 subjects, half with placebo... they analyzed 94 “positive” cases...no

Alex John London

AlexJohnLondon

When you make an argument like this, please show your work. Let’s think of the cases1. So we deploy an investigational vaccine that doesn’t actually confer immunity or strong immunity.

By continuing to use the site, you are consenting to the use of cookies as explained in our Cookie Policy to improve your experience.